Urology
Volume 61, Issue 4, Supplement 1 , Pages 2-7, April 2003

The role of dihydrotestosterone in benign prostatic hyperplasia

  • Culley Carson III

      Affiliations

    • Division of Urology, Department of Medicine, University of North Carolina, Chapel Hill North Carolina, USA (CC); Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, North Carolina, USA (RR)
    • C.C. Carson III is a member of the speaker’s bureau for, and is a study investigator funded by, GlaxoSmithKline.
    • Corresponding Author InformationReprint requests: Culley Carson III, MD, Division of Urology, Department of Medicine, University of North Carolina 2140, USA Bioinformatics Building, CB# 7235, Chapel Hill, North Carolina 27599-7235.
    • ,
  • Roger Rittmaster

      Affiliations

    • Division of Urology, Department of Medicine, University of North Carolina, Chapel Hill North Carolina, USA (CC); Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, North Carolina, USA (RR)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0090-4295(03)00045-1

doi:10.1016/S0090-4295(03)00045-1

Urology
Volume 61, Issue 4, Supplement 1 , Pages 2-7, April 2003

Article Tools

* Image Usage & Resolution